Boehringer's anti-clotting drug Pradaxa gains EU approval

08/4/2011 | Reuters

The European Commission approved Boehringer Ingelheim's Pradaxa for preventing stroke in people with atrial fibrillation. The approval underscores Boehringer's lead over other drugmakers in replacing anticoagulant warfarin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX